DigniCap – The Intelligent Scalp Cooling System™
The DigniCap® Scalp Cooling System is now available at both of our Lincoln locations. The DigniCap minimizes hair loss from certain chemotherapy treatments for men and women with solid tumor cancers such as those associated with breast, prostate, ovarian, uterine and other tissues.
Hair loss is no longer inevitable
Hair loss is a well-documented side effect of many chemotherapy drugs. Chemotherapy-induced hair loss can be significantly reduced in many cases. The DigniCap® Scalp Cooling System offers you the possibility to minimize hair loss from certain chemotherapy drugs.
For over a decade DigniCap has successfully helped thousands of patients globally and we are proud to offer the FDA-cleared DigniCap treatment as an option for our patients.
Scalp Cooling – How it works
Some chemotherapy drugs can damage your hair cells. Cooling of the scalp is a proven approach to reduce chemotherapy-induced hair loss.
Two reactions occur during scalp cooling:
- Reduced blood flow – Vasoconstriction in the scalp area limits the amount of chemotherapy agent delivered to the hair follicles.
- Reduced metabolism – Lower scalp temperature decreases the reaction rate causing normal cellular activity in the localized scalp area to slow dramatically.
With these two reactions, the follicles absorb fewer chemotherapy agents and hair loss is significantly reduced.
What is DigniCap?
The DigniCap Scalp Cooling System consists of a computerized cooling unit managed through a touch screen display and an attached cooling cap. Temperature-regulated coolant continuously circulates though specially designed channels in the cooling cap. The ability to maintain continuous, direct contact between the cooling cap and scalp for a consistent treatment temperature is a key factor in the effectiveness of DigniCap.
Who can use DigniCap?
The DigniCap Scalp Cooling System is indicated to reduce the likelihood of chemotherapy-induced hair loss in patients with solid tumors. Please note that scalp cooling is effective with many chemotherapy drugs, but not all. Your doctor can tell you if scalp cooling is compatible with your treatment.
Clinical Research Summary
The DigniCap Scalp Cooling System was studied in women with breast cancer at some of the most prestigious medical centers in the nation. In the pivotal trial, it was concluded that The DigniCap Scalp Cooling System prevented hair loss in 66.3% of patients with breast cancer receiving adjuvant chemotherapy compared to the control group where all experienced significant hair loss. Treatment was well tolerated with no scalp metastases observed. DigniCap was found to be highly effective in reducing chemotherapy-induced alopecia.
The DigniCap Scalp Cooling System was FDA cleared in December 2015 for women with breast cancer being treated with chemotherapy, the first such device to receive clearance. The FDA expanded the clinical indications for DigniCap in July 2017 to include men and women with solid tumors.
If you have questions about DigniCap, please contact us at 402-420-7000.